Our findings suggest that SSEA3/CD105 positivity is a potential marker of NTSC therapeutic efficacy for the treatment of AD. Future studies should focus on enhancing the therapeutic potential of SSEA3+/CD105+ NTSCs by improving their functional efficacy and consistency, and advancing their use in clinical settings.